_Protocols__UCDCC #171_ucdcc171stat

_Protocols__UCDCC #171_ucdcc171stat - UCD#171/GSK 104241...

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
UCD#171/GSK 104241 Lapatinib and Vinorelbine Phase I Version 2: December 26, 2005 29 The accrual rate to this trial is expected to be at least 4 patients per month. The phase I study is expected to accrue a minimum of 12 patients to a maximum 54 patients. In addition there will be 12 patients accrued in the “PK Cohort” of ARM A, once DLT is determined (for possible maximum total of 66 patients). The objective of this study is to assess the safety and feasibility of combining chronic oral lapatinib in combination with vinorelbine and determine the MTD (maximum tolerated dose). This trial will seek to determine the tolerability and MTD of lapatinib in combination with vinorelbine. Toxicities are to be graded according to the National Cancer Institute Common Terminology Criteria (NCI CTC, Version 3.0). A copy of the CTCAE version 3.0 can be downloaded from the CTEP home page (http://ctep.info.nih.gov). Dose Limiting Toxicity
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 12/30/2010 for the course BST 252 taught by Professor Tsodikov during the Winter '06 term at UC Davis.

Ask a homework question - tutors are online